EDIT Relative Valuation
EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EDIT is overvalued; if below, it's undervalued.
Historical Valuation
Editas Medicine Inc (EDIT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.53. The fair price of Editas Medicine Inc (EDIT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.49
Fair
-2.10
PE
1Y
3Y
5Y
Trailing
Forward
-0.75
EV/EBITDA
Editas Medicine Inc. (EDIT) has a current EV/EBITDA of -0.75. The 5-year average EV/EBITDA is -3.17. The thresholds are as follows: Strongly Undervalued below -12.95, Undervalued between -12.95 and -8.06, Fairly Valued between 1.72 and -8.06, Overvalued between 1.72 and 6.60, and Strongly Overvalued above 6.60. The current Forward EV/EBITDA of -0.75 falls within the Historic Trend Line -Fairly Valued range.
-0.71
EV/EBIT
Editas Medicine Inc. (EDIT) has a current EV/EBIT of -0.71. The 5-year average EV/EBIT is -3.07. The thresholds are as follows: Strongly Undervalued below -12.53, Undervalued between -12.53 and -7.80, Fairly Valued between 1.65 and -7.80, Overvalued between 1.65 and 6.38, and Strongly Overvalued above 6.38. The current Forward EV/EBIT of -0.71 falls within the Historic Trend Line -Fairly Valued range.
12.70
PS
Editas Medicine Inc. (EDIT) has a current PS of 12.70. The 5-year average PS is 60.25. The thresholds are as follows: Strongly Undervalued below -72.22, Undervalued between -72.22 and -5.98, Fairly Valued between 126.49 and -5.98, Overvalued between 126.49 and 192.72, and Strongly Overvalued above 192.72. The current Forward PS of 12.70 falls within the Historic Trend Line -Fairly Valued range.
-2.32
P/OCF
Editas Medicine Inc. (EDIT) has a current P/OCF of -2.32. The 5-year average P/OCF is -6.03. The thresholds are as follows: Strongly Undervalued below -18.31, Undervalued between -18.31 and -12.17, Fairly Valued between 0.10 and -12.17, Overvalued between 0.10 and 6.24, and Strongly Overvalued above 6.24. The current Forward P/OCF of -2.32 falls within the Historic Trend Line -Fairly Valued range.
-2.25
P/FCF
Editas Medicine Inc. (EDIT) has a current P/FCF of -2.25. The 5-year average P/FCF is -6.23. The thresholds are as follows: Strongly Undervalued below -19.43, Undervalued between -19.43 and -12.83, Fairly Valued between 0.37 and -12.83, Overvalued between 0.37 and 6.97, and Strongly Overvalued above 6.97. The current Forward P/FCF of -2.25 falls within the Historic Trend Line -Fairly Valued range.
Editas Medicine Inc (EDIT) has a current Price-to-Book (P/B) ratio of 16.40. Compared to its 3-year average P/B ratio of 3.71 , the current P/B ratio is approximately 342.12% higher. Relative to its 5-year average P/B ratio of 3.89, the current P/B ratio is about 320.96% higher. Editas Medicine Inc (EDIT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -64.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -43.26% , the current FCF yield is about -100.00% lower.
16.85
P/B
Median3y
3.71
Median5y
3.89
-78.27
FCF Yield
Median3y
-64.70
Median5y
-43.26
Competitors Valuation Multiple
The average P/S ratio for EDIT's competitors is 0.00, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 12265.57%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EDIT increased by 91.34% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 61.00K to 7.54M.
The secondary factor is the Margin Expansion, contributed -99.67%to the performance.
Overall, the performance of EDIT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Editas Medicine Inc (EDIT) currently overvalued or undervalued?
What is Editas Medicine Inc (EDIT) fair value?
How does EDIT's valuation metrics compare to the industry average?
What is the current P/B ratio for Editas Medicine Inc (EDIT) as of Dec 05 2025?
What is the current FCF Yield for Editas Medicine Inc (EDIT) as of Dec 05 2025?
What is the current Forward P/E ratio for Editas Medicine Inc (EDIT) as of Dec 05 2025?